Table 4 Multivariable regression analysis of factors affecting outcome for patients treated with immunotherapy (N = 77 with TMB available)

 Cutaneous SCC versus others

3.96 (0.69–22.64)

0.12

 TMB ≥ 10 mutations/mb versus < 10

4.51 (1.40–14.61)

0.01

 PD-1/L1 monotherapy versus combination

0.15 (0.04–0.58)

0.006

 Male versus female

0.94 (0.53–1.68)

0.83

 Caucasian versus others

0.69 (0.33–1.43)

0.32

 NSCLC versus others

1.52 (0.86–2.67)

0.15

 Cutaneous SCC versus others

0.71 (0.22–2.26)

0.56

 TMB ≥ 10 mutations/mb versus others

0.47 (0.26–0.86)

0.01

 PHBR < 0.5 versus ≥ 0.5

0.75 (0.41–1.38)

0.36

 Male versus female

0.64 (0.33–1.26)

0.20

 Caucasian versus others

0.68 (0.27–1.72)

0.42

 TMB ≥ 10 mutations/mb versus < 10

0.48 (0.24–0.970)

0.04